Compass announced a $10B all-stock acquisition of Anywhere, adding over 340,000 agents. The deal is expected to close in late 2026 but may face antitrust scrutiny and possible asset divestitures in ...
In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results